— Early Experiments Demonstrate Rapid Potential for High-Volume Production of ImmCelz® with Consistent Power —
PHOENIX, April 20, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) CELZ, a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology and orthopedics, today announced progress in the development of a reproducible product of clinical quality of ImmCelz®. Several clinical experiments have been performed in which the ImmCelz® The product was manufactured in less than 72 hours, using the company’s cell-free supercharging solution. The amount of ImmCelz® product was significantly higher than the control in many replicates of the experiments. There was also the possibility to check the repeated potency of the final ImmCelz® product.
Timothy WarbingtonPresident and CEO of the company, said, “We are delighted to receive this excellent news, which further validates our immunotherapy platform and paves the way for the advancement of clinical studies. We look forward to continuing to work closely with the team members of the University of Miami who bring decades of combined experience to our projects. We believe our Immcelz® program has enormous potential to improve patient outcomes across multiple indications, including stroke, type I diabetes, heart disease, liver disease and kidney disease. »
ImmCelz®, which is protected by trade secrets and published US patents, uses adult stem cells from qualified donors to impart specific properties to the patient’s immune cells. Once the cells harvested from the patient have been incubated with the company’s cell-free reprogramming “cocktail”, the cells are returned to the patient. These “supercharged” cells subsequently “educate” other cells of the immune system to stop attacking the body, while preserving the ability to attack foreign pathogens.
The company plans to advance multiple indications for ImmCelz® beginning with stroke, which is currently under review by the FDA. After gaining approval to proceed with clinical trials in stroke, the company plans to accelerate additional therapies under the ImmCelz® umbrella, including for type I diabetes, heart disease, liver disease and kidney disease.
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics. For more information about the company, please visit www.creativemedicaltechnology.com.
This press release may contain forward-looking statements, including, but not limited to, comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements relate to future events and conditions and, therefore, involve risks and uncertainties. Actual results may differ materially from those currently anticipated in these statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.
View original content for multimedia download: https://www.prnewswire.com/news-releases/creative-medical-technology-announces-progress-in-developing-a-reproducible-clinical-grade-of-the-companys -immcelz-product-301528924.html
SOURCE Creative Medical Technology Holdings, Inc.